Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Company Overview - Adverum Biotechnologies, Inc. is a clinical-stage company focused on pioneering gene therapy as a new standard of care for prevalent ocular diseases [3] - The company aims to develop functional cures to restore vision and prevent blindness, utilizing its proprietary intravitreal (IVT) platform [3] - Adverum is working on a novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), intended as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration [3] Upcoming Events - Adverum will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:40 p.m. ET [1] - The presentation will be accessible via a webcast, which will be available for replay on the company's website for at least 30 days following the event [2]